Drugs / MK-3795
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02293980 | Nov 2014 → Jan 2017 overdue | clear cell renal carcinoma | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03108066 | Apr 2017 → Aug 2023 | clear cell renal carcinoma, von Hippel-Lindau disease | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3795 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03108066 ↗ |
| Route | Oral | “Oral administration” NCT02293980 ↗ |